ABIONYX Pharma Undisclosed

ABIONYX Pharma has launched a capital increase aiming to raise up to $33.0 million. This funding round follows previous capital raises, indicating it is a follow-on round. The company plans to use these funds to advance its innovative therapies for sepsis and intensive care, leveraging its proprietary apoA-I technology platform.